Why the study?
Does percutaneous Inoue-balloon mitral valvuloplasty provide safe and effective outcomes in patients with mitral stenosis and concomitant moderate mitral regurgitation compared to those without?
Does percutaneous Inoue-balloon mitral valvuloplasty provide safe and effective outcomes in patients with mitral stenosis and concomitant moderate mitral regurgitation compared to those without?
Percutaneous Inoue-balloon mitral valvuloplasty using a height-derived sizing method is safe and effective in selected patients with mitral stenosis and concomitant moderate mitral regurgitation, without causing severe MR.
May support Inoue-balloon valvuloplasty in selected mitral stenosis with moderate MR; leaves open randomized confirmation of efficacy differences.
The present study compares the outcome of percutaneous Inoue-balloon mitral valvuloplasty performed in 21 patients with (group A) and 83 patients without (group B) preexisting moderate mitral regurgitation, using our height-derived balloon-sizing method. All procedures were successfully completed without untoward complications. The immediate increments in mitral valve area measured by echocardiographic methods and optimal valvuloplasty results were significantly higher in group B compared with group A (0.9 cm2 vs. 0.7 cm2, P = 0.01, and 99% vs. 90%, P = 0.007, respectively). No patients in either group sustained a final grade > or = 3/4 angiographic mitral regurgitation. A mild increase in mitral regurgitation was encountered more commonly in group B than in group A patients (22% vs. 0%, P = 0.03). At a mean follow-up of 19-20 months, the substantial majority of patients (> or = 90%) in both groups continued to experience maintained symptomatic benefits. In conclusion, our preliminary data seem to indicate that percutaneous Inoue-balloon mitral valvuloplasty using our height-derived balloon-sizing method in the stepwise dilatation approach in selected patients with significant mitral stenosis and concomitant moderate mitral regurgitation is associated with a low risk of developing severe mitral regurgitation, with effective mitral valve enlargement, and with sustained midterm symptomatic benefits.
No takes yet. Share an insight, caveat, or question.
Lau et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: